Home » Newsletters » BioWorld Science

BioWorld Science

May 12, 1999

View Archived Issues

Pharming: Q1 1999 highlights

AEterna updates shareholders

Axcan and Vianex sign letter of intent related to H. pylori treatment

Trimelamol analogue available for licensing from CRCT

Anesta enters partnership with Swedish Orphan for Actiq

POH enters additional phase II trials

Gilead extends Preveon expanded access program internationally

Lyme disease vaccine technology available for licensing from Brookhaven National Laboratory

Hollis-Eden initiates phase I/II AIDS trial, reports preclinical results

AstraZeneca launches Casodex 80 mg in Japan for treatment of prostate cancer

Paxil approved in two major markets for social anxiety disorder

Cephalon initiates testing of modafinil for excessive daytime sleepiness in sleep apnea sufferers

New carbapenems with excellent in vitro and in vivo profile designed by Korean scientists

Boehringer Ingelheim: Annual Report 1998

Selective human 5-HT1B receptor ligands in development at AstraZeneca

Antagonists of MIP-1alpha/RANTES receptor disclosed by Takeda

SmithKline Beecham identifies new anticonvulsant ureas

Stability and ocular uptake of BAPSG evaluated in preclinical studies

Asahi Glass describes dual NK1/NK2 antagonists

New class of CETP inhibitors useful for lipid disorders and coronary artery disease

NZ-419 proves effective in diabetic patients with chronic renal failure

Targeted delivery of TNP-470 using water-soluble polymer effective in choroidal neovascularization

Novel aciclovir derivative from Norsk Hydro effective against primary and recurrent genital herpes

Rhone-Poulenc's board approves full merger with Hoechst to form Aventis

Cardiovascular drugs and new drug targets focus of CuraGen-Cor Therapeutics agreement

NIAID seeks authorization to begin first clinical trials of GAS vaccine in over 20 years

Teva's Copaxone receives marketing approval in Switzerland for RRMS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 30, 2026.
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026